ZTS - Educational Analysis * US Equities
Educational Analysis * US Equities

ZTS

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerZTS
CategoryEducational primer
Last reviewedNovember 10, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

Zoetis Inc. operates in Healthcare, specifically the Drug Manufacturers – Specialty & Generic industry, but its business is animal health rather than human pharmaceuticals. The company discovers, develops, manufactures and commercializes medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal-health tools. Its products are sold across eight core species—dogs, cats and horses on the companion-animal side, and cattle, swine, poultry, fish and sheep on the livestock side—in more than 100 countries.

The revenue mix is unusually concentrated in companion animals. In 2025, companion animal products generated roughly 70% of total revenue, while livestock contributed about 29%. Brand concentration is also meaningful: Simparica/Simparica Trio alone accounted for approximately 16% of revenue, Apoquel/Apoquel Chewable for about 12%, and the top five product lines together contributed roughly 42% of revenue.

The financial footprint supports the idea that these brands carry real pricing power. Zoetis reports a net margin of 26.1% and a return on equity of 76.4%. Those figures are high for most healthcare manufacturers and suggest that the company’s portfolio carries durable demand, repeat-purchase behavior from veterinarians and pet owners, and efficient capital use. At the same time, the 42% revenue contribution from five product lines is a structural concentration risk: any regulatory setback, generic challenge or market-share loss among those franchises would have an outsized impact.

Financial posture

As of the current snapshot, Zoetis carries a market capitalization of $34.0 billion and trades at a price-to-earnings ratio of 14.0, with the stock at $82.32. The P/E multiple is below what many large-cap animal-health or specialty-drug names have historically commanded, which is why recent commentary has framed the stock as a quality business trading at a compressed valuation.

Profitability metrics reinforce the quality narrative: a 26.1% net margin and 76.4% ROE place the company well above the average healthcare manufacturer. Beta is 0.68, meaning the stock has moved with less volatility than the broader market. The 50-day exponential moving average is $77.49, so the current price sits above that short-term trend level, while the RSI of 56.1 indicates neutral momentum.

None of these numbers, by themselves, make a stock cheap or expensive, but the combination of high margins, elevated ROE, a low-beta profile and a 14.0x P/E is what has recently attracted “quality-at-a-discount” commentary.

Strategic priorities & outlook

Zoetis’s most recent 10-K outlines a straightforward set of operational priorities. The company intends to keep investing in the discovery and development of new chemical, biopharmaceutical and biological entities, while also extending the commercial life of existing products through lifecycle innovation.

Vaccines are a second priority. Management describes a “first to know and fast to market” approach for emerging infectious diseases, which is especially relevant for livestock portfolios where disease outbreaks can reshape demand quickly. A third thread is diagnostics: Zoetis is integrating new AI-driven capabilities into its Vetscan Imagyst platform to expand point-of-care testing in veterinary clinics. Finally, in 2026 the company plans to eliminate the one-month reporting lag for subsidiaries outside the U.S. and align fiscal years across its U.S. and International segments. That accounting change should make quarterly results more directly comparable, though it may create short-term re-measurement effects.

Operationally, the U.S. segment produced $5,097 million in 2025 revenue, or 54% of the total, while International revenue was $4,254 million, or 45%. The near-term story is therefore U.S.-led, but currency and international macro conditions still matter.

Macro & geopolitical exposure

As a specialty and generic drug manufacturer with global distribution, Zoetis faces the same macro forces that shape pharmaceuticals more broadly. Regulatory scrutiny of pricing, manufacturing standards and product approvals is a persistent factor. Currency exposure is material: roughly 45% of revenue comes from outside the U.S., so a stronger dollar weakens reported international results.

Trade policy can also affect costs and supply chains. Active pharmaceutical ingredients, packaging materials and finished products often move across borders, so tariffs or logistical constraints can pressure margins even if demand stays intact. Patent and generic-competition timelines matter too; while companion-animal products enjoy franchise loyalty, they are not immune to generic challenge over time.

The livestock business adds a separate layer. Demand for swine, poultry, cattle and fish health products is tied to protein prices, herd sizes and feed costs. Animal disease outbreaks—whether avian influenza, African swine fever or other emerging pathogens—can drive short-term vaccine demand but can also disrupt customer economics. In short, Zoetis’s macro profile is defensive in some respects and cyclical in others.

Recent developments

The most recent news cluster centers on the company’s Q3 2026 earnings release and call. On November 6, 2026, Seeking Alpha published both the earnings-call transcript and a piece titled “Zoetis: Quality Company Trading Cheap.” On November 8, MarketBeat summarized “What Zoetis (ZTS) Said on Its Q3 Earnings Call,” while Zacks.com’s November 9 headline highlighted “Competitive Pressures and Outlook.”

The Q3 results themselves were strong on the headline: actual EPS of $1.75 versus an estimate of $1.51, a 15.9% positive surprise. Yet the stock fell 3.3% the next day and was flat over the following five sessions. That reaction fits the broader pattern seen in the news: even a solid quarter is being filtered through concerns about competition, pricing pressure and forward guidance.

Earnings behavior & post-earnings drift

Zoetis has an impressive recent earnings record. Over the last eight reported quarters, the company beat expectations seven times, for an 88% beat rate, with an average earnings surprise of 4.9%. Despite that track record, the average five-day price move following earnings across those quarters is -4.3%, classified as a downward post-earnings drift.

The last four quarters illustrate why. For the November 5, 2026 report, EPS of $1.75 beat the $1.51 estimate by 15.9%, but the stock dropped 3.3% the next day and finished the next five trading days unchanged. The prior quarter, reported August 6, 2026, saw a $1.87 actual versus a $1.85 estimate, a 1.1% beat, yet the stock fell 5.97% the next day and 1.85% over the next five sessions. The May 7, 2026 quarter was the outlier miss: actual EPS of $1.53 versus $1.60, a -4.4% surprise, prompting a next-day decline of 5.13% and a five-day drop of 13.55%. Only the February 12, 2026 report produced a positive post-earnings sequence: $1.48 versus $1.40, a 5.7% beat, with the stock rising 0.8% the next day and 2.5% over the following five days.

That divergence—strong beat rate but negative average drift—suggests that the market’s real expectation is often higher than the published consensus, or that management’s forward commentary has overshadowed the reported quarter. The next scheduled report is February 11, 2027 before the open, with a current consensus EPS estimate of $1.25.

Frequently Asked Questions

What does Zoetis primarily sell?

Zoetis sells animal-health medicines, vaccines, diagnostics and related services. Companion animal products made up roughly 70% of 2025 revenue, livestock around 29%, and the top five product lines contributed about 42% of revenue.

How has ZTS performed after recent earnings reports?

Over the last eight quarters Zoetis beat estimates seven times (88% beat rate) with an average earnings surprise of 4.9%, yet the average five-day move after earnings is -4.3%. Reactions have ranged from a 2.5% gain after the February 2026 report to a 13.55% decline following the May 2026 miss.

What are Zoetis’s main strategic priorities?

According to its latest 10-K, Zoetis is focused on R&D for new chemical, biopharmaceutical and biological entities; faster vaccine development for emerging infectious diseases; AI-driven enhancements to the Vetscan Imagyst diagnostics platform; and aligning the fiscal reporting periods of its U.S. and International subsidiaries in 2026.

For a deeper dive, readers may want to review the full institutional verdict on ZTS, which includes detailed analyst ratings, target ranges and forward estimates beyond the figures covered here.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 10, 2026
Zoetis Inc. · Healthcare / Drug Manufacturers - Specialty & Generic
$34.0BMarket cap
14.0P/E
26.1%Net margin
76.4%ROE
88%Beat rate, last 8Q
4.9%Avg EPS surprise
-4.3%Avg 5-day move after earnings
2027-02-11Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-11-05$1.75$1.51+15.9%-3.3%null%
2026-08-06$1.87$1.85+1.1%-5.97%-1.85%
2026-05-07$1.53$1.6-4.4%-5.13%-13.55%
2026-02-12$1.48$1.4+5.7%+0.8%+2.5%
2025-11-04$1.7$1.62+4.9%--
2025-08-05$1.76$1.62+8.6%--

Previous ZTS editions

Beyond the primer

Get the institutional verdict on ZTS

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the ZTS verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.